ERYTECH Pharma est membre de Lyonbiopôle

General information

Batiment Adénine, 60 avenue Rockefeller

69008 LYON

Incorporated in: 2004/11/15

Number of employees: 113

More information


Main activity

Founded in 2004, Erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. Erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. Its first product, working by starving tumors, has completed its phase III development and will provide a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia. The company has a production unit located in Lyon with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements, with Orphan Europe-Recordati (in Europe) and TEVA (in Israel).  


Looking for funding: Yes

Nature of funding searches: Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs    

Private funding obtained: June 2006 : 12 Millions Euros ; June 2010 : 5.2 Millions Euros ; April 2013 : 17.7 Millions Euros (IPO) ; October 2014 : 30 Millions Euros December 2015 : 25.4 Millions Euros December 2016 : 9.9 Millions Euros April 2017 : 70 Millions Euros November 2017 : 144 Millions US Dollars (IPO)

Public funding obtained: 2008: 600 k€ / subsidy ; 2009: 767 k€ / sub ; 215 k€ / repayable advance ; 2010: 77 k€ / sub ; 2011: Oseo:   2 M€:sub / 5  M€ : repayable advance  

Stock exchange listing: 30/04/2013: IPO in compartment C of the NYSE Euronext regulated market in Paris (17.7 Millions Euros) 10/11/2017 : IPO in US Nasdaq Global Select Market (144 Millions US Dollars)

Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine

Application market
Immune, AutoIm & Inflam. diseases - Oncology - Metabolic Diseases

Therapeutics, Pharma or Biotech

Cell Therapy - cell biology - Biobanking - Drug delivery device - services - Antibodies - Protein - Peptide

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à Plus de détails sont disponibles en cliquant ici J'accepte